[MASK (Mobile Airways Sentinel Network), a mobile App with ARIA's comprehensive solution in Spanish-speaking countries]. / MASK (Mobile Airways Sentinel Network), una app móvil con la solución integral de ARIA en países de habla hispana.

Although there are high quality clinical guidelines about allergic rhinitis, many patients receive deficient treatment, partly due to the high level of self-medication. MASK (Mobile Airways Sentinel Network) is an integral part of a project against chronic diseases which it is focused on active and healthy aging and is supported by the European Union. It forms the third phase of ARIA (Allergic Rhinitis and its Impact on Asthma) in which, through a mobile app on a smart device, the purpose is to guide patients in the control of their multimorbidity, allergic rhinitis or conjunctivitis, or asthma. The "Allergy Diary" app by MACVIA-ARIA is free and it is available for Android and iOS; on it, patients indicate how unpleasant the symptoms are on a daily basis through five screens with an analogous visual scale; two more screens were recently added (sleep affectation). With the app, it is also possible to download the information of the "Allergy Diary" on the physician's computer through a QR code at the moment of the medical consultation. In this article, we review the first year of experience in Spain, Mexico and Argentina, where the Spanish version is used.

Aunque existen guías clínicas de alta calidad sobre rinitis alérgica, numerosos pacientes reciben tratamiento deficiente, en parte debido al alto grado de automedicación. MASK (Mobile Airways Sentinel Network) forma parte integral de un proyecto apoyado por la Unión Europea contra las enfermedades crónicas y enfocado al envejecimiento activo y saludable. Constituye la tercera fase de ARIA (Allergic Rhinitis and its Impact on Asthma), en la cual mediante una aplicación móvil en un dispositivo inteligente se intenta guiar al paciente en el control de su multimorbilidad, rinitis o conjuntivitis alérgicas o asma. La aplicación Diario de Alergia por MACVIA-ARIA es gratuita y está disponible para Android e iOS; en ella, los pacientes indican diariamente cuánto les molestan los síntomas a través de cinco pantallas con una escala visual análoga; recientemente se agregaron dos pantallas más (afectación del sueño). La aplicación también permite descargar los datos del "Diario de alergias" en la computadora del médico en el momento de la consulta a través de un código QR. En este artículo reseñamos el primer año de experiencia en España, México y Argentina, que utilizan la versión española.

[MASK (Mobile Airways Sentinel Network). ARIA's comprehensive solution for mobile app for the multimorbidity of allergic rhinitis and asthma]. / MASK (Mobile Airways Sentinel Network). La solución integral de ARIA por app móvil para la multimorbilidad de rinitis alérgica y asma.

The vast majority of patients with allergic rhinitis (AR) do not receive the proper management which is recommended by the guidelines, but they frequently self-medicate. MASK (Mobile Airways Sentinel Network) is an integral part of a project that is supported by the European Union against chronic diseases and focused on active and healthy aging. MASK represents the third phase of ARIA (Allergic Rhinitis and its Impact on Asthma), in which, by using a mobile application in a smart device, the objective is to guide the patient in the control of his/her multi-morbidity, AR and/or allergic conjunctivitis (AC) and/or asthma. The mobile app Allergy Diary by MACVIA-ARIA is free and it is available for both Android and iOS platforms. After it is downloaded to the patient's cell phone, it first requests some information about the patient's profile, allergic pathologies and medication; afterwards, through a visual analog scale, the patient is invited to determine the degree of affectation in the nose, eyes, and bronchi, and its influence on their productivity at work / school. After analyzing the data generated by filling the Allergy Diary, it became clear there is a new clinical entity: allergic rhinitis+ allergic conjunctivitis +asthma, with greater effect; in addition to a high level of self-medication: in general, the patient takes medication on days when symptoms are present. The app has already been deployed in 23 countries, including several Spanish-speaking countries.

La mayoría de los pacientes con rinitis alérgica no recibe el manejo idóneo, sino que se automedica. MASK (Mobile Airways Sentinel Network) forma parte integral de un proyecto apoyado por la Unión Europea contra las enfermedades crónicas y enfocado al envejecimiento activo y saludable. Constituye la tercera fase de ARIA (Allergic Rhinitis and its Impact on Asthma), en la cual mediante una aplicación móvil en un dispositivo inteligente se intenta guiar al paciente en el control de su multimorbilidad, rinitis o conjuntivitis alérgicas o asma. La aplicación Diario de Alergia por MACVIA-ARIA es gratuita y está disponible para Android e iOS. Al descargarla al celular del paciente, a este se le piden datos de su perfil, patologías alérgicas y medicación; posteriormente, mediante una escala visual analógica se le invita a determinar el grado de afectación en nariz, ojos y bronquios y su influencia sobre su productividad laboral/escolar. Con los datos del Diario de Alergia se observa que existe un nuevo patrón de presentación: rinitis alérgica + conjuntivitis alérgica + asma, con mayor afectación, así como un alto nivel de automedicación: en general, el paciente toma medicación cuando presenta síntomas. La app se ha desplegado en 23 países, incluyendo varios países hispanohablantes.

Rinitis, poliposis nasal y su relación con el asma / Asthma, rhinitis, and nasal polyp multimorbidities

El objetivo de esta revisión es facilitar al neumólogo el manejo de las enfermedades de la vía respiratoria superior ligadas a la vía respiratoria inferior, especialmente al asma, unidas por una epidemiología, una clínica y un mecanismo inflamatorio comunes e interrelacionados. El documento recoge las definiciones de los diferentes fenotipos nasosinusales ligados al asma: rinitis alérgica o no alérgica y rinosinusitis crónica con o sin pólipos nasales. Asimismo se recogen los criterios diagnósticos y su nivel de gravedad. Se dedica especial atención a los dos síndromes principales asociados al asma: 1) rinitis alérgica, la patología más frecuente, y 2) rinosinusitis crónica con pólipos nasales, la patología más ligada al asma grave. En síntesis, en el manejo del asma debe valorarse siempre la vía respiratoria superior con la finalidad de un diagnóstico unificado y un tratamiento integral de la vía respiratoria única

The aim of this review is to assist pulmonologists in the management of diseases involving both the upper and lower respiratory tract that are linked by a common, interrelated epidemiology, clinical signs and symptoms, and inflammatory mechanism − asthma, in particular. The document discusses the definitions of the various sinonasal phenotypes associated with asthma: allergic and non-allergic rhinitis and chronic rhinosinusitis with or without nasal polyps. Diagnostic criteria and severity levels are also listed. Particular attention has been given to the 2 main syndromes associated with asthma: (I) allergic rhinitis, the most common, and (II) chronic rhinosinusitis with nasal polyps, the disease most closely associated with severe asthma. To summarize, the upper respiratory tract should always be evaluated in order to achieve a single diagnosis and comprehensive treatment of the "united airway"

[Executive Summary of ARIA 2019: Integrated care pathways for allergic rhinitis in Argentina, Spain and Mexico]. / Resumen ejecutivo de ARIA 2019: Vías integradas de atención para la rinitis alérgica en Argentina, España y México.

The health and economic impact of allergic diseases are increasing rapidly, and changes in management strategies are required. Its influence reduces the capacity of work and school performance by at least a third. The ICPs of the airways (integrated care pathways for respiratory diseases) are structured multidisciplinary healthcare plans, promoting the recommendations of the guidelines in local protocols and their application to clinical practice. This document presents an executive summary for Argentina, Mexico, and Spain. Next-generation ARIA guidelines are being developed for the pharmacological treatment of allergic rhinitis (AR), using the GRADE-based guidelines for AR, tested with real-life evidence provided by mobile technology with visual analogue scales. It is concluded that in the AR treatment, H1-antihistamines are less effective than intranasal corticosteroids (INCS), in severe AR the INCS represent the first line of treatment, and intranasal combination INCS + anti-H1 is more effective than monotherapy. However, according to the MASK real-life observational study, patients have poor adherence to treatment and often self-medicate, according to their needs.

El impacto sanitario y económico de las enfermedades alérgicas está aumentando rápidamente y se necesitan cambios en las estrategias para su manejo. Su influencia reduce al menos en un tercio la capacidad de desempeño laboral y escolar. Los ICP (Vías Integradas de Atención) de las enfermedades de las vías respiratorias son planes de atención estructurados y multidisciplinarios, que promueven las recomendaciones de las guías en protocolos locales y su aplicación a la práctica clínica. En este documento se presenta un resumen ejecutivo para Argentina, México y España. Se desarrollan las guías ARIA de próxima generación para el tratamiento farmacológico de la rinitis alérgica (RA) utilizando las pautas basadas en GRADE para RA, probadas con evidencia de la vida real proporcionada por tecnología móvil basada en escalas visuales analógicas. Se concluye que en el tratamiento de la RA, los antihistamínicos anti-H1 son menos efectivos que los corticoides intranasales (CINS), que en la rinitis gravelos CINS representan la primera línea de tratamiento, y que la combinación intranasal de CINS + anti-H1 es más eficaz que la monoterapia. Sin embargo, según el estudio MASK observacional en vida real, los pacientes tienen pobre adherencia al tratamiento y frecuentemente se automedican de acuerdo con sus necesidades.

Asthma, rhinitis, and nasal polyp multimorbidities. / Rinitis, poliposis nasal y su relación con el asma.

The aim of this review is to assist pulmonologists in the management of diseases involving both the upper and lower respiratory tract that are linked by a common, interrelated epidemiology, clinical signs and symptoms, and inflammatory mechanism - asthma, in particular. The document discusses the definitions of the various sinonasal phenotypes associated with asthma: allergic and non-allergic rhinitis and chronic rhinosinusitis with or without nasal polyps. Diagnostic criteria and severity levels are also listed. Particular attention has been given to the 2 main syndromes associated with asthma: (i)allergic rhinitis, the most common, and (ii)chronic rhinosinusitis with nasal polyps, the disease most closely associated with severe asthma. To summarize, the upper respiratory tract should always be evaluated in order to achieve a single diagnosis and comprehensive treatment of the "united airway".

[Rhinitis and asthma comorbidity in Spain: the RINAIR study]. / Comorbilidad de rinitis y asma en España (estudio RINAIR).

OBJECTIVE: Rhinitis and asthma share an inflammatory mechanism, epidemiological patterns, and symptoms that affect both the nose and the bronchi. The RINAIR study examined the prevalence and characteristics of rhinitis in asthma patients in Spain. PATIENTS AND METHODS: This prospective epidemiological study was carried out with the participation of 15% of Spanish respiratory medicine specialists sampled randomly from different geographic areas. The study population was composed of 703 asthmatic patients aged over 16 years who were enrolled between February and September 2005. Patient characteristics, prevalence of rhinitis, lung function, allergy test results, and treatment of rhinitis were analyzed. RESULTS: Seventy-one percent (n=499) of the asthmatic patients had rhinitis. These patients were younger (43.8 years vs 55.4 years; P< .0001) and had less severe asthma (forced expiratory volume in 1 second [FEV1], 85.7% vs 79.7% [P< .001]) than asthmatic patients who did not have rhinitis. A correlation was observed between the severity of asthma and the severity of rhinitis (P< .001). Atopy was significantly associated with rhinitis (odds ratio, 6.25; 95% confidence interval, 4.3-9.1): 84% of atopic patients and 51% of nonatopic patients had rhinitis. Treatment of rhinitis was associated with an increase in FEV1 (P=.057), irrespective of sex, age, severity of asthma, or smoking. CONCLUSIONS: Seventy-one percent of asthmatic patients who attended respiratory medicine clinics had rhinitis. These patients were younger and had milder asthma than asthmatics who did not have rhinitis. Furthermore, atopy was correlated with asthma associated with rhinitis. Treatment of rhinitis led to improved lung function. These findings highlight the need to study and treat the upper and lower respiratory tract as a single airway.

Comorbilidad de rinitis y asma en España (estudio RINAIR) / Rhinitis and asthma comorbidity in Spain: the RINAIR study

OBJETIVO: Rinitis y asma están ligadas por una epidemiología,clínica y mecanismo inflamatorio comunes que interrelacionannariz y bronquio. El objetivo del estudio RINAIRha sido estudiar la prevalencia y características de larinitis en pacientes con asma en España.PACIENTES Y MÉTODOS: Se ha realizado un estudio epidemiológicode carácter prospectivo con la participación del15% de los neumólogos españoles, distribuidos aleatoriamentepor áreas geográficas. Se incluyó a 703 asmáticos mayoresde 16 años entre febrero y septiembre de 2005. Se analizarondatos demográficos, prevalencia de rinitis, funciónpulmonar, pruebas alérgicas y tratamiento de la rinitis.RESULTADOS: Un 71% (n = 499) de los asmáticos presentabarinitis. Éstos eran más jóvenes (43,8 frente a 55,4 años; p< 0,0001) y presentaban un asma menos grave —volumenespiratorio forzado en el primer segundo (FEV1): un 85,7frente a un 79,7% (p < 0,001)— que los asmáticos sin rinitis.Se observó una correlación entre la gravedad del asma y lagravedad de la rinitis (p < 0,001). La atopia se asoció significativamentecon la presencia de rinitis (odds ratio = 6,25; intervalode confianza del 95%, 4,3-9,1): el 84% de los atópicosy el 51% de los no atópicos tenían rinitis. El tratamientode la rinitis se asoció (p = 0,057) con un incremento delFEV1, con independencia del sexo, la edad, la gravedad delasma y el hábito de fumar.CONCLUSIONES: Un 71% de los asmáticos atendidos en lasconsultas de neumología tiene rinitis. Estos pacientes sonmás jóvenes y presentan un asma más leve que los asmáticossin rinitis. Por otro lado, la atopia se relaciona con el asmaasociada a rinitis. El tratamiento de la rinitis tiende a mejorarla función pulmonar. Estos hallazgos indican la necesidad deestudiar y tratar toda la vía respiratoria de forma integral

OBJECTIVE: Rhinitis and asthma share an inflammatorymechanism, epidemiological patterns, and symptoms thataffect both the nose and the bronchi. The RINAIR studyexamined the prevalence and characteristics of rhinitis inasthma patients in Spain.PATIENTS AND METHODS: This prospective epidemiologicalstudy was carried out with the participation of 15% ofSpanish respiratory medicine specialists sampled randomlyfrom different geographic areas. The study population wascomposed of 703 asthmatic patients aged over 16 years whowere enrolled between February and September 2005.Patient characteristics, prevalence of rhinitis, lung function,allergy test results, and treatment of rhinitis were analyzed.RESULTS: Seventy-one percent (n=499) of the asthmaticpatients had rhinitis. These patients were younger (43.8 yearsvs 55.4 years; P<.0001) and had less severe asthma (forcedexpiratory volume in 1 second [FEV1], 85.7% vs 79.7%[P<.001]) than asthmatic patients who did not have rhinitis.A correlation was observed between the severity of asthmaand the severity of rhinitis (P<.001). Atopy was significantlyassociated with rhinitis (odds ratio, 6.25; 95% confidenceinterval, 4.3-9.1): 84% of atopic patients and 51% ofnonatopic patients had rhinitis. Treatment of rhinitis wasassociated with an increase in FEV1 (P=.057), irrespective ofsex, age, severity of asthma, or smoking.CONCLUSIONS: Seventy-one percent of asthmatic patientswho attended respiratory medicine clinics had rhinitis.These patients were younger and had milder asthma thanasthmatics who did not have rhinitis. Furthermore, atopywas correlated with asthma associated with rhinitis.Treatment of rhinitis led to improved lung function. Thesefindings highlight the need to study and treat the upper and lower respiratory tract as a single airway